Gyre Therapeutics Updates Corporate Presentation on Sept 1, 2026

What Happened

• On September 1, 2026, Gyre Therapeutics, Inc. announced (via a Form 8-K, Item 7.01) that it made an updated corporate presentation available on the company’s website. A copy of the presentation is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Date of disclosure: September 1, 2026.
• Filing: Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure).
• Exhibit furnished: 99.1 — Corporate Presentation dated September 2026.
• The filing also includes the cover page interactive data file (Exhibit 104) as part of the submission.

Why It Matters

• The company used a Regulation FD disclosure to broadly share updated corporate information; investors should review the presentation for any refreshed details on strategy, pipeline, or corporate priorities.
• This 8-K does not report earnings, revenue, executive changes, mergers, or other financial results—its sole purpose is to furnish the updated presentation.
• Retail investors who follow Gyre may want to read Exhibit 99.1 on the company website or the SEC filings to see if the presentation contains material corporate or operational updates.